Related Experiment Video
Updated: May 17, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Adiponectin and long-term mortality in coronary artery disease participants and controls
Sébastien Hascoet1, Meyer Elbaz, Vanina Bongard
1Department of Cardiology, Rangueil Hospital, 1 avenue Jean Poulhes, 31000 Toulouse, France. shascoet.cardiotoulouse@yahoo.fr
Insights
High serum adiponectin predicts mortality, especially from cardiovascular disease, in both coronary artery disease (CAD) patients and controls. This prognostic value is independent of CAD severity and metabolic status.
Area of Science:
- Cardiology
- Biomarkers
- Epidemiology
Background:
- Adiponectin possesses cardioprotective properties, but its role as a cardiovascular disease marker remains debated due to conflicting study results.
- Previous research on adiponectin and cardiovascular outcomes has yielded inconsistent findings, necessitating further investigation.
Purpose of the Study:
- To determine if serum adiponectin levels are associated with long-term mortality in individuals with stable coronary artery disease (CAD) and control subjects.
- To evaluate the prognostic value of adiponectin considering varying degrees of CAD severity.
Main Methods:
- A case-control design was employed with a median prospective follow-up of 8.1 years.
- Serum adiponectin levels were measured in 715 CAD patients and 782 controls.
- Statistical analyses included survival rate comparisons across adiponectin quartiles and multivariate adjustments.
Main Results:
- Survival rates decreased significantly with increasing quartiles of serum adiponectin in CAD patients (P<0.001).
- Higher adiponectin levels (≥9.1 µg/mL) were associated with lower survival rates in controls (P=0.035).
- Elevated adiponectin concentrations predicted increased risk of total and cardiovascular disease mortality in both CAD patients and controls, even after adjustments.
Conclusions:
- High serum adiponectin is a significant predictor of mortality, particularly cardiovascular disease mortality.
- The prognostic significance of adiponectin persists regardless of coronary artery disease severity or metabolic status.
- The association between high adiponectin and mortality risk does not differ between individuals with and without CAD.
Objective:
Despite cardioprotective properties, studies investigating adiponectin as a cardiovascular disease marker led to conflicting results. We investigated in participants with stable coronary artery disease (CAD) and controls whether serum adiponectin was associated with long-term mortality, considering varying degrees of CAD severity.
Methods And Results:
A case-control design with prospective median follow-up of 8.1 years was used. Survival rates among 715 CAD men (aged 45-74 years) in increasing quartiles of serum adiponectin values were 87.5%, 85.6%, 76.4%, and 67.6%, respectively (P<0.001). Survival rates in 782 controls with adiponectin <9.1 µg/mL and ≥9.1 µg/mL (third quartile) were 95.3% and 91.0%, respectively (P=0.035). Adiponectin concentration above the highest quartile was associated with an increased risk of total and cardiovascular disease mortality in CAD patients (P=0.001 and P=0.001) and controls (P=0.02 and P=0.004). The associations among high adiponectin, total mortality, and cardiovascular disease mortality remained significant after multivariate adjustments for metabolic, cardiac, and CAD severity variables. No significant interaction was found among CAD patients, controls, and the relationship of adiponectin with mortality.
Conclusions:
High serum adiponectin is a predictor of mortality, particularly from cardiovascular disease. This prognostic value remains significant whatever the severity of the CAD and the metabolic status and is not different among people with and without CAD.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Coronary Artery Disease I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease III: Clinical Manifestations
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation